🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

InxMed (Shanghai) clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with InxMed (Shanghai) as lead sponsor. Synced 26 Sep 2026
9Current trials
7Recruiting now
10Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

InxMed (Shanghai) is the lead sponsor of 9 current clinical trials in our China register. 7 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are IN10018, Albumin-Bound Paclitaxel and Carboplatin. The most-studied condition is NSCLC.

ClinicalTrials.gov trials by status

  • Recruiting778%
  • Not yet open111%
  • Active, closed111%

Trials by phase

  • Phase 1/2667%
  • Phase 3111%
  • Phase 2111%
  • Phase 1111%
01

Clinical trials sponsored by InxMed (Shanghai)

9 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
NCT05994131 · ClinicalTrials.gov ↗ · NSCLC
Phase 1/2 Recruiting 2023-07 China
IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors
NCT07441174 · ClinicalTrials.gov ↗ · Solid Tumor Cancer, PDAC
Phase 1/2 Recruiting 2026-02 China
IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
NCT05827796 · ClinicalTrials.gov ↗ · Pancreatic Cancer
Phase 1/2 Recruiting 2022-12 China
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07174908 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 3 Recruiting 2025-09 China
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
NCT06030258 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage
Phase 1/2 Recruiting 2023-10 China
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
NCT06014528 · ClinicalTrials.gov ↗ · Ovarian Cancer Recurrent
Phase 2 Recruiting 2022-09 China
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
NCT05551507 · ClinicalTrials.gov ↗ · Platinum-resistant Ovarian Cancer
Drug: IN10018
Phase 1/2 Recruiting 2020-07 China
FAK Inhibitor in Patients With Advanced Solid Tumors
NCT07596381 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1 Not yet open 2026-05 China
a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors
NCT06166836 · ClinicalTrials.gov ↗ · Solid Tumor
Phase 1/2 Active, closed 2022-10 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in InxMed (Shanghai) trials

10 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in InxMed (Shanghai) trials

10 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China97

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in NSCLC

SponsorTrials
Sichuan University3
Allist Pharmaceuticals3
Tubulis2
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)2
TYK Medicines2
Jiangsu Cancer Institute & Hospital2
Ellipses Pharma1
Eikon Therapeutics1
Shanghai Huaota Biopharmaceutical1
Monte Rosa Therapeutics1

Sponsors with the most current trials registered for this condition.

06

Questions about InxMed (Shanghai) trials

How many clinical trials does InxMed (Shanghai) sponsor?

InxMed (Shanghai) is the lead sponsor of 9 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are InxMed (Shanghai) trials recruiting?

Yes. 7 of its 9 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is InxMed (Shanghai) testing?

Its current trials name 10 drugs and biologicals as interventions. The most frequent are IN10018 (6), Albumin-Bound Paclitaxel (1), Carboplatin (1), Etoposide (1) and Furmonertinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.